A Four-Chemokine Signature Is Associated with a T-cell-Inflamed Phenotype in Primary and Metastatic Pancreatic Cancer.
Biomarkers, Tumor
/ genetics
CD8-Positive T-Lymphocytes
/ immunology
Chemokine CCL4
/ genetics
Chemokine CCL5
/ genetics
Chemokine CXCL10
/ genetics
Chemokine CXCL9
/ genetics
Cohort Studies
Computational Biology
/ methods
Databases, Genetic
/ statistics & numerical data
Humans
Immune Checkpoint Proteins
/ genetics
Immunotherapy
/ methods
Liver Neoplasms
/ genetics
Mutation
Pancreatic Neoplasms
/ genetics
RNA-Seq
/ methods
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
15 04 2020
15 04 2020
Historique:
received:
26
08
2019
revised:
14
12
2019
accepted:
15
01
2020
pubmed:
23
1
2020
medline:
28
1
2021
entrez:
23
1
2020
Statut:
ppublish
Résumé
The molecular drivers of antitumor immunity in pancreatic ductal adenocarcinoma (PDAC) are poorly understood, posing a major obstacle for the identification of patients potentially amenable for immune-checkpoint blockade or other novel strategies. Here, we explore the association of chemokine expression with effector T-cell infiltration in PDAC. Discovery cohorts comprised 113 primary resected PDAC and 107 PDAC liver metastases. Validation cohorts comprised 182 PDAC from The Cancer Genome Atlas and 92 PDACs from the Australian International Cancer Genome Consortium. We explored associations between immune cell counts by immunohistochemistry, chemokine expression, and transcriptional hallmarks of antitumor immunity by RNA sequencing (RNA-seq), and mutational burden by whole-genome sequencing. Among all known human chemokines, a coregulated set of four ( A conserved 4-chemokine signature marks resectable and metastatic PDAC tumors with an active antitumor phenotype. This could have implications for the appropriate selection of PDAC patients in immunotherapy trials.
Identifiants
pubmed: 31964786
pii: 1078-0432.CCR-19-2803
doi: 10.1158/1078-0432.CCR-19-2803
doi:
Substances chimiques
Biomarkers, Tumor
0
CCL4 protein, human
0
CCL5 protein, human
0
CXCL10 protein, human
0
CXCL9 protein, human
0
Chemokine CCL4
0
Chemokine CCL5
0
Chemokine CXCL10
0
Chemokine CXCL9
0
Immune Checkpoint Proteins
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1997-2010Subventions
Organisme : NCI NIH HHS
ID : R01 CA190449
Pays : United States
Organisme : CIHR
Pays : Canada
Informations de copyright
©2020 American Association for Cancer Research.